NEJM Publishes New Data on GARDASIL, Cervical Cancer Vaccine
Gardasil and Cervical Cancer Vaccination
Today, the New England Journal of Medicine is publishing results from two Phase III studies of Merck's cervical cancer vaccine, GARDASIL (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine). In the first study, GARDASIL provided 100 percent protection against cervical, vaginal and vulvar diseases caused by the four HPV types GARDASIL is designed to protect against, HPV types 6, 11, 16, and 18. In the second study, GARDASIL provided 98 percent protection against advanced cervical pre-cancers caused by the two primary cancer-causing HPV types, HPV 16 and 18. These significant results, observed in 15- to 26-year-old women who were not infected with the relevant HPV types when they began the study, were sustained through an average of three years of participation in the trials, including an additional year of follow up since data were presented to the U.S. Food and Drug Administration (FDA) for approval of GARDASIL.